Pharmacy Solution for Behavioral Health

Offering Stigma-Free, Compliance-Focused Pharmacy Services

Cordant Health Solutions™ partners with clinician practices and other stakeholders to provide a pharmacy solution that specializes in safely and securely dispensing medications for the treatment of behavioral health conditions, including medication-assisted treatment (MAT) for opioid and substance use disorders.

Integrating Cordant’s suite of drug testing, pharmacy and data analytics solutions can help promote patient safety, engagement and adherence to treatment protocols and increases visibility into patient behavior for early intervention.

Stigma-Free Buprenorphine Program

Cordant’s stigma-free buprenorphine distribution program improves access to the medications used to treat opioid use disorder.

Pharmacy Service in Your Clinic

An on-site Cordant team member may be able to collect drug testing specimens as ordered by the clinician and also deliver prescribed buprenorphine where the program is offered. Onsite delivery services remove many of the barriers treatment patients face that keep them from accessing their medication.

PDMP Review for Every Prescription

Cordant pharmacists check prescriptions against the state’s prescription drug monitoring program (PDMP) data and alert clinicians to potential risks.

Prior Authorizations

The Cordant pharmacy team may be able to help with time-consuming medication prior authorizations, giving valuable time and resources back to your staff.

Better Patient Outcomes

Cordant’s integrated pharmacy and drug testing program supports improved medication adherence and reduced patient risk.

One Pharmacy

Cordant can fill many other maintenance medications for mental health and other chronic conditions, including diabetes (oral medications only), heart disease, high cholesterol, digestive disorders and gastrointestinal diseases, allergies and arthritis.

Cordant’s stigma-free buprenorphine distribution program improves access to the medications used to treat opioid use disorder.

0 %
Patients receiving buprenorphine combined with risk-based drug testing consistently test positive for the drug

Analysis of 96 integrated patients; Jan. 2017–Sept. 2018

0 %
Higher medication adherence rates among patients in Cordant’s stigma-free buprenorphine distribution program compared with independent study data

Analysis of 496 pharmacy patients; Jan 2017 – Sept 2018 | Hser, Y. et al. (2013), Treatment retention among patients randomized to buprenorphine/ naloxone compared to methadone in multi-site trial. Addiction; 109(1): 79-87

What Our Patients Are Saying